Üvea/Behçet
Derleme
Printed Date: 2.03.2018
Unresponsiveness to Treatment, Pharmaceutical Alterations and Combined Treatments in Behçet’s Disease
Abstract
Behçet’s disease is a multisystem inflammatory disease with chronic recurrences. Because of the chronic course, the treatment is very difficult. Classical treatment options are corticosteroids, azothiopurine and cyclosporin. Immunosuppressive agents should be used in addition to steroids in this disease. The aim of the treatment is to protect the visual acuity, reduce the attack frequency, reduce the severity of the attack and to taper off the steroids as early as possible. Although agents used in classical therapy have limited adrenocorticotropic side effects, they each have serious potential side effects, require strict follow-up, and may develop resistance or non-response to these agents. In patients with resistant Behçet’s disease, which can not be controlled by conventional treatment, the first choice should be interferon or biological agents. In this review, treatment options for patients with resistant Behcet’s disease that can not be controlled by conventional therapy
are discussed.
Keywords: Resistant disease, drug changes, interferon, biological agents
. . .
Article Information
Received : 30.01.2018
Accepted : 2.03.2018
First Published (online): 2.03.2018
Printed : 1.10.2018
Accepted : 2.03.2018
First Published (online): 2.03.2018
Printed : 1.10.2018
Citation : Soylu M, Çoban Karataş M. Behçet Hastalığında Tedaviye Yanıtsızlık, İlaç Değişimleri ve Kombine Tedaviler. Güncel Retina 2018;2(4):366-370.